APTAH

EUIPO EUIPO 2022 Trademark registered

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The Union trademark APTAH was filed as Word mark on 03/11/2022 at the European Union Intellectual Property Office.
It was registered as a trademark on 08/11/2022. The current status of the mark is "Trademark registered".

Trademark Details Last update: August 15, 2022

Trademark form Word mark
File reference 018670606
Application date March 11, 2022
Publication date May 4, 2022
Entry date August 11, 2022
Expiration date March 11, 2032

Trademark owner

930 Brittan Ave.
94070 San Carlos
US

Trademark representatives

Leopoldstr. 4 80802 München DE

goods and services

1 Biomolecules for medical and scientific research
5 Pharmaceutical preparations for the configuration, modulation and correction of rna transcript splicing and other post-transcription processes; pharmaceutical preparations for the configuration, modulation and correction of rna for the treatment of genetic diseases; pharmaceutical preparations for restoring and reprograming rna-protein interactions for the treatment of diseases; pharmaceutical preparations for the treatment of diseases associated with gene dysregulation, inhibition or suppression of gene expression; pharmaceutical preparations for the treatment of genetic diseases; gene therapy products, namely, molecules for controlling gene expression; molecular diagnostic tests for testing bodily fluid for the detection of diseases; medical diagnostic tests for the detection of neurodegenerative, oncological and infectious diseases
42 Research and development of pharmaceuticals, namely, therapies for the configuration, modulation and correction of rna transcript splicing and other post-transcription processes; research and development of therapies in the fields of biotechnology, genetic medicine, gene therapy, dna, rna, molecules and proteins; design and development of biomolecules for medical and scientific use, and medical treatment; drug design and development featuring biomolecules

ID: 11018670606